CONSOLIDATED STATEMENT OF EQUITY - USD ($) $ in Thousands	Total	Acquisitions And Asset Purchases	DeepHealth, Inc.	Radnet, Inc. Stockholders' Equity	Radnet, Inc. Stockholders' Equity Acquisitions And Asset Purchases	Radnet, Inc. Stockholders' Equity DeepHealth, Inc.	Common Stock	Common Stock Acquisitions And Asset Purchases	Common Stock DeepHealth, Inc.	Additional Paid-in Capital	Additional Paid-in Capital Acquisitions And Asset Purchases	Additional Paid-in Capital DeepHealth, Inc.	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020							51,640,537
Beginning balance at Dec. 31, 2020	$ 258,303			$ 165,743			$ 5			$ 307,788			$ (24,051)	$ (117,999)	$ 92,560
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)							53,960
Issuance of stock upon exercise of options	488			488						488
Shares issued under the equity compensation plan (in shares)							1,212,758		471,162
Stock-based compensation expense	25,284			25,284						25,284
Issuance of common stock for acquisitions (in shares)								82,658	91,517
Issuance of common stock for acquisitions		$ 2,498	$ 2,413		$ 2,498	$ 2,413					$ 2,498	$ 2,413
Contribution from noncontrolling partner	123														123
Distributions paid to noncontrolling interests	(2,426)														(2,426)
Change in cumulative foreign currency translation adjustment	(65)			(65)									(65)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,695			3,695									3,695
Net income (loss)	44,319			24,727										24,727	19,592
Gain on contribution of assets to majority owned subsidiary	(4)			(4)						(4)
Forfeiture of restricted stock (in shares)							(4,365)
Forfeiture of restricted stock	(81)			(81)						(81)
Sale to noncontrolling interests, net of taxes	11,610			4,206						4,206					7,404
Ending balance (in shares) at Dec. 31, 2021							53,548,227
Ending balance at Dec. 31, 2021	346,157			228,904			$ 5			342,592			(20,421)	(93,272)	117,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)							25,000
Issuance of stock upon exercise of options	295			295			$ 1			294
Shares issued under the equity compensation plan (in shares)							725,577		204,160
Issuance of common stock to settle DeepHealth contingent consideration (in shares)									781,577
Stock-based compensation expense	23,543			23,543						23,543
Issuance of common stock for acquisitions (in shares)								2,465,294
Issuance of common stock for acquisitions		$ 63,311			$ 63,311						$ 63,311
Contribution from noncontrolling partner	19,139														19,139
Distributions paid to noncontrolling interests	(893)														(893)
Change in cumulative foreign currency translation adjustment	(3,943)			(3,943)									(3,943)
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,687			3,687									3,687
Net income (loss)	33,608			10,650										10,650	22,958
Forfeiture of restricted stock (in shares)							(26,710)
Forfeiture of restricted stock	(75)			(75)						(75)
Sale to noncontrolling interests, net of taxes	$ 6,623			6,623						6,623
Ending balance (in shares) at Dec. 31, 2022	57,723,125						57,723,125
Ending balance at Dec. 31, 2022	$ 491,452			332,995			$ 6			436,288			(20,677)	(82,622)	158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock upon exercise of options (in shares)	12,723		37,909				12,424
Issuance of stock upon exercise of options	$ 142			142						142
Shares issued under the equity compensation plan (in shares)							1,128,453		37,909
Stock-based compensation expense	26,785			26,785						26,785
Contribution from noncontrolling partner	2,885														2,885
Distributions paid to noncontrolling interests	(5,972)														(5,972)
Change in cumulative foreign currency translation adjustment	4,617			4,617									4,617
Change in fair value of cash flow hedge from prior periods reclassified to earnings	3,576			3,576									3,576
Net income (loss)	30,337			3,044										3,044	27,293
Issuance of common stock, net of issuance costs (in shares)							8,711,250
Issuance of common stock, net of issuance costs	245,832			245,832			$ 1			245,831
Issuance of common stock in connection with acquisitions (in shares)							378,699
Issuance of common stock in connection with acquisitions	11,470			11,470						11,470
Forfeiture of restricted stock (in shares)							(35,542)
Forfeiture of restricted stock	0			0
Sale to noncontrolling interests, net of taxes	2,236			2,236						2,236
Other	$ (1)			(2)						2				0	1
Ending balance (in shares) at Dec. 31, 2023	57,723,125						67,956,318
Ending balance at Dec. 31, 2023	$ 813,359			$ 630,695			$ 7			$ 722,750			$ (12,484)	$ (79,578)	$ 182,664